The estimated Net Worth of Jennifer M Chao is at least $1.02 Million dollars as of 7 June 2019. Ms. Chao owns over 459 units of Biospecifics Technologies stock worth over $2,656 and over the last 9 years she sold BSTC stock worth over $798,546. In addition, she makes $217,507 as Independent Chairman of the Board at Biospecifics Technologies.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Ms. Chao BSTC stock SEC Form 4 insiders trading
Jennifer has made over 6 trades of the Biospecifics Technologies stock since 2019, according to the Form 4 filled with the SEC. Most recently she sold 459 units of BSTC stock worth $26,874 on 7 June 2019.
The largest trade she's ever made was exercising 8,000 units of Biospecifics Technologies stock on 22 May 2019 worth over $301,120. On average, Jennifer trades about 1,900 units every 2 days since 2015. As of 7 June 2019 she still owns at least 30 units of Biospecifics Technologies stock.
You can see the complete history of Ms. Chao stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jennifer Chao biography
Jennifer M. Chao serves as Independent Chairman of the Board of the Company. Ms. Jennifer joined as a member of our Board in April 2015 and was appointed Chairman of the Board on October 21, 2019. A biotech industry expert, Ms. Chao is the founder of CoreStrategies Management, LLC (“CoreStrategies”), a strategic consulting firm providing transformational corporate and financial strategies to biotech/life science companies for maximizing core valuation. Previously, from 2004-2008, Ms. Chao was a Managing Director and Senior Lead Biotechnology Securities Analyst at Deutsche Bank, covering large- and small- to mid-cap biotechnology companies. Her widely published research has served as a bellwether for investment portfolio managers and the financial and health care industry. Prior to this, Ms. Chao was a Managing Director and Senior Lead Biotechnology Analyst at RBC Capital Markets and a Senior Analyst in Biotechnology at Leerink Swann & Co. Her industry forte includes game-changing life science technologies, rare genetic diseases, vaccines, neurology, pulmonology, cardiology, oncology, immunology, and HIV/HCV with a focus on new treatment paradigms, shifting treatment algorithms, new drug modalities, and healthcare legislation. Ms. Chao has held the following licenses, Series 7, 63, 86, and 87. Ms. Chao was a research fellow at Massachusetts General Hospital/Harvard Medical School as a recipient of the BioMedical Research Career Award and received her B.A. in Politics and Greek Classics from New York University.
What is the salary of Jennifer Chao?
As the Independent Chairman of the Board of Biospecifics Technologies, the total compensation of Jennifer Chao at Biospecifics Technologies is $217,507. There are no executives at Biospecifics Technologies getting paid more.
How old is Jennifer Chao?
Jennifer Chao is 50, she's been the Independent Chairman of the Board of Biospecifics Technologies since 2019. There are 8 older and no younger executives at Biospecifics Technologies. The oldest executive at Biospecifics Technologies Corp. is Toby Wegman, 85, who is the Director.
What's Jennifer Chao's mailing address?
Jennifer's mailing address filed with the SEC is C/O EDESA BIOTECH, INC. 100 SPY COURT, , MARKHAM, A6, L3R 5H6.
Insiders trading at Biospecifics Technologies
Over the last 33 years, insiders at Biospecifics Technologies have traded over $67,860,045 worth of Biospecifics Technologies stock and bought 7,761,661 units worth $656,708,120 . The most active insiders traders include Capital Management, Llc Kol..., International Plc Endo, and Max Link. On average, Biospecifics Technologies executives and independent directors trade stock every 73 days with the average trade being worth of $6,538,649. The most recent stock trade was executed by International Plc Endo on 2 December 2020, trading 7,344,955 units of BSTC stock currently worth $650,028,518.
What does Biospecifics Technologies's logo look like?
Complete history of Ms. Chao stock trades at Biospecifics Technologies, Endo International plc, and Edesa Biotech
Biospecifics Technologies executives and stock owners
Biospecifics Technologies executives and other stock owners filed with the SEC include:
-
Jennifer Chao,
Independent Chairman of the Board -
Michael Schamroth,
Independent Director -
Paul Gitman,
Independent Director -
Mark Wegman,
Director -
Toby Wegman,
Director -
Sarah McCabe,
Stern Investor Relations -
Michael Sherman,
Independent Director -
Corey Fishman,
Independent Director -
Alex Monteith,
Senior Vice President and Chief Business Officer -
Patrick Hutchison,
Chief Financial Officer -
Joseph Truitt,
Chief Executive Officer, Director -
Jeffrey Kenneth Vogel,
-
Jyrki Mattila,
Director -
Thomas Wegman,
President -
Of Edwin H. Wegman Estate,
10% owner -
Patrick M Caldwell,
Principal Financial Officer -
Partners Lp Bio,
10% owner -
Albert Horcher,
-
Lawrence Dobroff,
CFO -
Max Link,
Director -
Henry Morgan,
Director -
George M Gould,
Director -
Matthew Geller,
Director -
Capital Management, Llc Kol...,
-
Capital Management, Llcra C...,
-
Capital Management, Llcaldr...,
-
Capital Management, Llc Kol...,
-
Capital Management, Llcra C...,
-
J Kevin Buchi,
Chief Executive Officer -
International Plc Endo,
10% owner